Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are tough conditions to manage. Even with advanced treatments like tumor necrosis factor inhibitors (TNFis), many people don't get the relief they need. A recent study looked at how well these treatments work in the real world over a year
Psoriatic arthritis (PsA) is a tough condition to manage. It's an inflammatory disease that affects joints and skin. People with PsA often take medicines called csDMARDs to control their symptoms. But what if there's a new drug that could help even more? Deucravacitinib is a new oral medication. It
Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are complex conditions. They affect many people. Yet, there is a gap in understanding how these conditions are treated in real-world settings. This is especially true for biologic and targeted synthetic disease-modifying anti-rheumatic
You might think genes are just complicated terms, but they can actually tell us a lot about our health. Take, for example, the MTHFR and TP53 genes. The MTHFR gene helps with how the body uses folic acid, while the TP53 gene acts like a guardian, keeping our cells healthy. A recent study in South Af
Psoriatic arthritis, or PsA, is a complex inflammatory disease that can affect joints and skin, and it often comes with other health issues. Managing PsA is crucial to control the disease, prevent damage, and improve quality of life. Over time, many drugs have been developed to help. While some, lik
Psoriatic arthritis, or PsA, is a long-term health issue that can hit at any age. It's not just about joint pain—it's a whole package deal of physical and mental challenges. Picture this: you're having a tough time moving around due to inflammation in your joints. Add to that the psychological press
Imagine you have psoriasis and want to know if you might also get psoriatic arthritis (PsA). Researchers have come up with an interesting way to predict this using data from a big health survey called NHANES. They didn't stick to just one method, but tried out multiple ways to see which works best.
Psoriasis patients often worry about developing psoriatic arthritis (PsA). But which biologic treatment is best? Researchers looked at three types: IL-23 inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, comparing them to TNF inhibitors. The goal? To see who's at higher risk for PsA. First, le
